Fennec announces NICE recommends PEDMARQSI for cisplatin-induced hearing loss in children in England and Wales

FENNEC PHARMACEUTICALS INC.

NICE issued positive final draft guidance recommending PEDMARQSI for prevention of cisplatin-induced hearing loss in patients aged 1 month-17 years with localized solid tumors.
First and only approved therapy in EU/U.K. for cisplatin-induced ototoxicity prevention; Phase 3 trials showed ~50% reduction in hearing loss.
Fennec's partner Norgine will commercialize in Europe; Fennec received ~$43M upfront and is eligible for up to ~$230M milestones plus double-digit tiered royalties.
Until now, no preventative pharmacological intervention was available despite significant lifelong impact of hearing loss on pediatric cancer patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.